Lombard Odier Asset Management (Switzerland)’s CRISPR Therapeutics CRSP Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-54,786	Closed	-$2.48M	–	203
2023 Q1	$2.48M	Sell	54,786 -28,628	-34%	-$1.39M	0.22%	111
2022 Q4	$3.39M	Buy	83,414 +24,239	+41%	+$1.29M	0.27%	80
2022 Q3	$3.87M	Sell	59,175 -4,394	-7%	-$318K	0.33%	70
2022 Q2	$3.86M	Sell	63,569 -127,116	-67%	-$7.47M	0.33%	72
2022 Q1	$12M	Buy	190,685 +12,916	+7%	+$811K	0.94%	41
2021 Q4	$13.5M	Buy	+177,769	New	+$15.5M	0.86%	44

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s CRSP Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of CRISPR Therapeutics (CRSP) in Q2 2023, closing a stake of 54,786 shares — an estimated $2.48M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in CRSP in Q4 2021 and held it in 6 quarters. The position peaked at $13.5M in Q4 2021. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

Lombard Odier Asset Management (Switzerland) reported no remaining CRISPR Therapeutics position as of Q2 2023 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 54,786 CRISPR Therapeutics shares in Q2 2023, an estimated $2.48M.
Lombard Odier Asset Management (Switzerland) first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 6 quarters.
Lombard Odier Asset Management (Switzerland)'s CRISPR Therapeutics position peaked at $13.5M in Q4 2021.
418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.